295,00 995,00 

Delivery Time: 3-5 business days

Clear

SKU: 2175-380R Category:

Product details

Synonyms = Beta-Granin; CGA; CHGA; Chromogranin A Parathyroid Secretory Protein 1; ER-37; Pancreastatin; Parastatin; Parathyroid Secretory Protein 1; Pituitary Secretory Protein I; SP-I; Vasostatin I or II

Antibody type = Recombinant Rabbit monoclonal / IgG

Clone = MSVA-380R

Positive control = Appendix: An at least weak to moderate staining must be seen in the axons and ganglion cells of the peripheral nerves while mucosal neuroendocrine cells exhibit a strong staining (neuroendocrine cells are not sufficient as positive controls because they express CGA so strongly, that even inefficient staining will detect its expression)

Negative control = Appendix: Epithelial and smooth muscle cells should be negative.

Cellular localization = Finely granular cytoplasmic

Reactivity = Human

 

Application = Immunohistochemistry
Dilution = 1:100 – 1:200
Intended Use = Research Use Only

Relevance of Antibody

Chromogranin A is expressed on neuroendocrine cell types.

Biology Behind

Chromogranin A (CGA), a 48-75 kDa glycoprotein, is a member of the granin family of neuroendocrine secretory proteins. It is an important marker of the diffuse neuroendocrine system (DNES) and represents more than 50% of the soluble matrix protein in secretory granules of various types of neuroendocrine cells. Chromogranin A induces and promotes the generation of secretory vesicles of endocrine cells and neurons. Post-translational processing of the protein results in biologically active peptides that exert autocrine and paracrine functions. These peptides for example include chromostatin, chromacin, pancreastatin, catestatin, parastatin vasostatin-1, and vasostatin-2. The function of some of these peptides is known and affects mechanisms such as contraction and relaxation of vascular smooth muscle cells, microglial neurotoxin secretion, dopamine release from neural tissues or catecholamine release from the adrenal medulla.

Staining Pattern in Normal Tissues

Chromogranin A staining pattern in Normal Tissues with antibody MSVA-380R (images are shown in our “Normal Tissue Gallery”)

Brain Cerebrum Negative.
  Cerebellum Negative.
Endocrine Tissues Thyroid Negative.
  Parathyroid Strong chromogranin A positivity of all epithelial cells.
  Adrenal gland Strong chromogranin A positivity in the medulla while adrenocortical cells are negative.
  Pituitary gland Strong chromogranin A positivity of all epithelial cells of the adenohypophysis.
Respiratory system Respiratory epithelium Negative.
  Lung Negative.
Gastrointestinal Tract Salivary glands Negative.
  Esophagus Negative.
  Stomach Strong chromogranin A staining of scattered neuroendocrine cells. Variable (mostly weak) chromogranin A staining of axons and ganglion cells of the peripheral nerves in the gastrointestinal wall.
  Duodenum Strong chromogranin A staining of scattered neuroendocrine cells. Variable (mostly weak) chromogranin A staining of axons and ganglion cells of the peripheral nerves in the gastrointestinal wall.
  Small intestine Strong chromogranin A staining of scattered neuroendocrine cells. Variable (mostly weak) chromogranin A staining of axons and ganglion cells of the peripheral nerves in the gastrointestinal wall.
  Appendix Strong chromogranin A staining of scattered neuroendocrine cells. Variable (mostly weak) chromogranin A staining of axons and ganglion cells of the peripheral nerves in the gastrointestinal wall.
  Colon Strong chromogranin A staining of scattered neuroendocrine cells. Variable (mostly weak) chromogranin A staining of axons and ganglion cells of the peripheral nerves in the gastrointestinal wall.
  Rectum Strong chromogranin A staining of scattered neuroendocrine cells. Variable (mostly weak) chromogranin A staining of axons and ganglion cells of the peripheral nerves in the gastrointestinal wall.
  Liver Negative.
  Gallbladder Negative.
  Pancreas Strong chromogranin A positivity of islet cells.
Genitourinary Kidney Negative.
  Urothelium Negative.
Male genital Prostate Negative.
  Seminal vesicles Negative.
  Testis Negative.
  Epididymis Negative.
Female genital Breast Negative.
  Uterus, myometrium Negative.
  Uterus, ectocervix Negative.
  Uterus endocervix Negative.
  Uterus, endometrium Negative.
  Fallopian Tube Negative.
  Ovary Negative.
  Placenta early Negative.
  Placenta mature Negative.
  Amnion Negative.
  Chorion Negative.
Skin Epidermis Negative.
  Sebaceous glands Negative.
Muscle/connective tissue Heart muscle Negative.
  Skeletal muscle Negative.
  Smooth muscle Negative.
  Vessel walls Negative.
  Fat Negative.
  Stroma Weak to moderate chromogranin A staining of axons and ganglion cells of peripheral nerves can be seen.
  Endothelium Negative.
Bone marrow/ lymphoid tissue Bone marrow Negative.
  Lymph node Negative.
  Spleen Negative.
  Thymus Negative.
  Tonsil Negative.
Remarks  

 

These findings are largely congruent to the data described in the Human Protein Atlas (Tissue expression Chromogranin A) 

 

Suggested positive tissue control: Appendix: An at least weak to moderate staining must be seen in the axons and ganglion cells of the peripheral nerves while mucosal neuroendocrine cells exhibit a strong staining (neuroendocrine cells are not sufficient as positive controls because they express CGA so strongly, that even inefficient staining will detect its expression)

Suggested negative tissue control: Appendix: Epithelial and smooth muscle cells should be negative.

 

Normal tissue gallery

Staining Pattern in Relevant Tumor Types

Chromogranin is typically expressed at high levels in pheochromocytoma, paraganglioma, neuroendocrine tumors, neuroendocrine carcinomas, medullary carcinomas of the thyroid, pituitary adenomas, Merkel cell carcinomas and in small cell carcinomas irrespective of their site of origin. Chromogranin is also seen in various neuronal tumors such as neuroblastoma, ganglioneuroblastoma, ganglioneuroma, and ganglioglioma. Chromogranin may also be detected in brain tumors like oligodendroglioma, astrocytoma and ependymoma, however, to a varying extent. Moreover, chromogranin can be detected in a small fraction of various other tumor entities, such as for example breast, colorectal, prostate or ovarian cancers if these tumors exhibit neuroendocrine differentiation.

The TCGA findings on Chromogranin A RNA expression in different tumor categories have been summarized in the Human Protein Atlas.

Cancer tissue gallery

Compatibility of Antibodies

No data available at the moment

Protocol Recommendations

IHC users have different preferences on how the stains should look like. Some prefer high staining intensity of the target stain and even accept some background. Others favor absolute specificity and lighter target stains. Factors that invariably lead to more intense staining include higher concentration of the antibody and visualization tools, longer incubation time, higher temperature during incubation, higher temperature and longer duration of the heat induced epitope retrieval (slide pretreatment). The impact of the pH during slide pretreatment has variable effects and depends on the antibody and the target protein.

 

All images and data shown here and in our image galleries are obtained by the manual protocol described below. Other protocols resulting in equivalent staining are described as well.

 

-Manual protocol

Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7,8 Target Retrieval Solution buffer. Apply MSVA-380R at a dilution of 1:150 at 37°C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer’s directions.

-Impact of pH

 

For antibody MSVA-380R pH9 is optimal but pH7,8 results in only slightly weaker stainings. At pH6, Chromogranin A  immunostaining is markedly reduced but still acceptable.

Potential Research Applications

  • The prevalence and clinical significance of chromogranin A immunostaining in cancers of different types should be thoroughly evaluated.
  • The role of neuroendocrine trans-differentiation in cancer is of critical interest, especially in prostate cancer.

Evidence for Antibody Specificity in IHC

There are two ways how the specificity of antibodies can be documented for immunohistochemistry on formalin fixed tissues. These are: 1. comparison with a second independent method for target expression measurement across a large number of different tissue types (orthogonal strategy), and 2. Comparison with one or several independent antibodies for the same target and showing that all positive staining results are also seen with other antibodies for the same target (independent antibody strategy). 

 

For the antibody MSVA-380R specificity is documented by the strong concordance of the immunostaining with RNA expression data derived from the Human Protein Atlas (HPA) RNA-seq tissue dataset, the FANTOM5 project, and the Genotype-Tissue Expression (GTEx) project which are all summarized in the Human Protein Atlas (Tissue expression Chromogranin A)  Immunostaining by using MSVA-380R was only detected in organs with documented RNA expression.

 

Moreover, no staining was seen in tissues notorious for non-specific IHC background such as kidney and the epidermis. 

 

Normal tissue gallery